Qiagen NV (QGEN)
-NasdaqGS | Prev Close: | 18.68 |
|---|
| Open: | N/A |
|---|
| Bid: | 18.61 x 400 |
|---|
| Ask: | 18.65 x 2200 |
|---|
| 1y Target Est: | 20.90 |
|---|
| Beta: | 0.87 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 15.66 - 22.20 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 812,041 |
|---|
| Market Cap: | 4.37B |
|---|
| P/E (ttm): | 37.36 |
|---|
| EPS (ttm): | 0.50 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 5 Stocks Improving Performance Of The Diversified Services Industryat TheStreet(Wed, May 22)
- QIAGEN Downgraded to Strong SellZacks(Tue, May 21)
- Qiagen Moves Up In Market Cap Rank, Passing Avery Dennisonat Forbes(Wed, May 15)
- QIAGEN Posts 2012 Annual Report on Its WebsiteGlobeNewswire(Wed, May 15)
- Roche Wins FDA Approval for Test to Target Lung Cancerat Bloomberg(Wed, May 15)
- Short Interest In Qiagen Decreases By 13.8%at Forbes(Fri, May 10)
- Qiagen: Limited Visibility On When Improvement Will Materializeat Seeking Alpha(Thu, May 9)
- Recent Financials May Not Be Entirely Fair To Hologicat Investopedia(Wed, May 8)
- QGEN Makes Notable Cross Below Critical Moving Averageat TheStreet(Wed, May 1)
- Qiagen Misses Earnings, Guides LowZacks(Wed, May 1)
- The Zacks Analyst Blog Highlights: LinkedIn, AOL, Facebook, Paychex and QiagenZacks(Wed, May 1)
- Qiagen NV Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, Apr 30)
- Qiagen Acquires IngenuitySystemsZacks(Tue, Apr 30)
- Qiagen Earnings: Here’s Why Investors Don’t Like These Resultsat Wall St. Cheat Sheet(Mon, Apr 29)
- QIAGEN Proposes Changes to Members of Supervisory BoardPR Newswire(Mon, Apr 29)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| QGEN | 0.00% | 4.37B |
| MHP | | N/A |
| MYGN | 0.00% | 2.57B |
| ACTG | 0.00% | 1.16B |
Key Statistics
| Forward P/E (1 yr): | 16.10 |
|---|
| P/S (ttm): | 3.47 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.06 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.23 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | 1.98 |
|---|
Business Summary
QIAGEN N.V., through its subsidiaries, provides sample and assay technologies worldwide. It offers approximately 500 core consumable products, such as sample and assay kits, and automated instrumentation systems that empower customers to transform...
View More 
0.52%